Rezolute, Inc. (RZLT)

NCM – Real Time Price. Currency in USD

4.00

-0.04 (-0.99%)

At close: Sep 23, 2026, 4:00 PM EDT

4.00

0.00 (0.00%)

After-hours: Sep 23, 2026, 4:14 PM EDT

09.09.2026

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Data from the Phase 3 sunRIZE study remains under review by FDA The OLE Phase of the study is ongoing, with a high participation rate and several indicators of improved glycemic control, including a notable reduction in the use of background standard of care therapies Enrollment continues in the Phase 3 upLIFT study in tumor HI and the Company remains on track to report topline results before the end of 2026 REDWOOD CITY, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (“HI”), today provided an update on the status of the ongoing U.S. Food and Drug Administration (“FDA” or “Agency”) review of data from the Company's Phase 3 sunRIZE study of ersodetug for the treatment of hypoglycemia due to congenital HI.

02.09.2026

Rezolute to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today announced that management will participate in the following investor conferences:

Videos

No Data

There is no data to display

Press releases

09.09.2026

Rezolute, Inc. (RZLT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Rezolute, Inc. (RZLT)

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Rezolute to Participate in Upcoming Investor Conferences

Videos

No Data

Press releases

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Rezolute to Participate in Upcoming Investor Conferences

Videos

No Data

Press releases

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Search stocks

Rezolute, Inc. (RZLT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Rezolute, Inc. (RZLT)

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Rezolute to Participate in Upcoming Investor Conferences

Videos

No Data

Press releases

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Rezolute to Participate in Upcoming Investor Conferences

Videos

No Data

Press releases

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism